[HTML][HTML] Parallels in sepsis and COVID-19 conditions: implications for managing severe COVID-19

CO Olwal, NN Nganyewo, K Tapela… - Frontiers in …, 2021 - frontiersin.org
Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to
infection. Sepsis is a global burden killing~ 11 million persons annually. In December 2019 …

Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19

M Manik, RK Singh - Journal of medical virology, 2022 - Wiley Online Library
Balanced immune regulation is crucial for recognizing an invading pathogen, its killing, and
elimination. Toll‐like receptors (TLRs) are the key regulators of the innate immune system. It …

[HTML][HTML] SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells

T Patra, K Meyer, L Geerling, TS Isbell, DF Hoft… - PLoS …, 2020 - journals.plos.org
Cytokine storm is suggested as one of the major pathological characteristics of SARS-CoV-2
infection, although the mechanism for initiation of a hyper-inflammatory response, and multi …

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

MT Kelleni - Expert Review of Anti-infective Therapy, 2022 - Taylor & Francis
Introduction Mediators of immunity and inflammation are playing a crucial role in COVID-19
pathogenesis and complications as demonstrated by several genetic and clinical studies …

[HTML][HTML] Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection

M Akbarzadeh-Khiavi, M Torabi, L Rahbarnia, A Safary - Infection, 2022 - Springer
Abstract Purpose The Coronavirus disease 2019 (COVID-19) pandemic is one of the most
devastating global problems. Regarding the lack of disease-specific treatments, repurposing …

[HTML][HTML] Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

A D'Alessio, P Del Poggio, F Bracchi, G Cesana… - Leukemia, 2021 - nature.com
SARS-CoV-2 is a biphasic illness characterized by a first flu-like phase, followed by a
pulmonary and systemic disease, in which a dysregulated cytokine storm may lead to acute …

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?

E Carboni, AR Carta, E Carboni - Medical Hypotheses, 2020 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a
pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths …

[HTML][HTML] Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity

CW Yang, YZ Lee, HY Hsu, C Shih, YS Chao… - Scientific reports, 2017 - nature.com
Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses. NF-
κB activation is a common pro-inflammatory response of host cells to viral infection. The …

[HTML][HTML] A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab

L Villaescusa, F Zaragozá, I Gayo-Abeleira… - Advances in …, 2022 - Springer
Since the beginning of the pandemic, numerous national and international clinical trials
have been conducted with a large number of drugs. Many of them are intended for the …

Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19

A Saha, AR Sharma, M Bhattacharya, G Sharma… - Archives of medical …, 2020 - Elsevier
Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity
and mortality of the disease is associated with a high level of release of cytokine in the …